Noninvasix discovered LIVOx™ Central Venous Oxygenation Monitor for the constant, non-invasive, real-time, or spot monitoring of central venous oxygen saturation (ScvO2) in adults with high risk of septic shock.
Non-invasive measuring of ScvO2 will open new paths to more efficient diagnosis of septic shock, thereby providing better patient care and reducing the overall healthcare costs.
There are no non-invasive approaches which provides ScvO2 information quickly. The current available methods for diagnosing low ScvO2 and monitoring treatment are either non-invasive which do not directly measure ScvO2 and prone to potential complications and time-consuming (placement of a central venous catheter directly into the patient’s blood stream, either for intermittent blood sampling or continuous oximetry.
U.S. Food and Drug Administration (FDA) has granted breakthrough device designation for non-invasive, real-time, continuous or spot monitoring of central venous oxygen saturation (ScvO2) in adults at risk of septic shock.
Nearly 1.7 million adults in U.S are affected with sepsis leading to 270,000 deaths annually. It is assumed to be the serious condition ranks as the third leading cause of death in the U.S. The LIVOx Central Venous Oxygenation Monitor will provide for a more effective diagnosis of this life-threatening condition.